دورية أكاديمية
Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution.
| العنوان: | Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. |
|---|---|
| المؤلفون: | Detante O; INSERM, U836, Grenoble Cedex 9, France. ODetante@chu-grenoble.fr, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, Barbier E, Desruet MD, De Fraipont F, Segebarth C, Jaillard A, Hommel M, Ghezzi C, Remy C |
| المصدر: | Cell transplantation [Cell Transplant] 2009; Vol. 18 (12), pp. 1369-79. Date of Electronic Publication: 2009 Sep 28. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Publishing Country of Publication: United States NLM ID: 9208854 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-3892 (Electronic) Linking ISSN: 09636897 NLM ISO Abbreviation: Cell Transplant Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Thousand Oaks, CA : SAGE Publishing Original Publication: Elmsford, New York : Pergamon Press, c1992- |
| مواضيع طبية MeSH: | Mesenchymal Stem Cell Transplantation*, Mesenchymal Stem Cells/*cytology , Radiopharmaceuticals/*administration & dosage , Stroke/*therapy , Technetium Tc 99m Exametazime/*administration & dosage, Animals ; Humans ; Injections, Intravenous ; Magnetic Resonance Imaging ; Rats ; Rats, Sprague-Dawley ; Stroke/pathology ; Tissue Distribution ; Whole-Body Counting |
| مستخلص: | Human mesenchymal stem cells (hMSC) are a promising source for cell therapy after stroke. To deliver these cells, an IV injection appears safer than a local graft. We aimed to assess the whole-body biodistribution of IV-injected (99m)Tc-HMPAO-labeled hMSC in normal rats (n = 9) and following a right middle cerebral artery occlusion (MCAo, n = 9). Whole-body nuclear imaging, isolated organ counting (at 2 and 20 h after injection) and histology were performed. A higher activity was observed in the right damaged hemisphere of the MCAo group [6.5 +/- 0.9 x 10(-3) % of injected dose (ID)/g] than in the control group (3.6 +/- 1.2 x 10(-3) %ID/g), 20 h after injection. In MCAo rats, right hemisphere activity was higher than that observed in the contralateral hemisphere at 2 h after injection (11.6 +/- 2.8 vs. 9.8 +/- 1.7 x 10(-3) %ID/g). Following an initial hMSC lung accumulation, there was a decrease in pulmonary activity from 2 to 20 h after injection in both groups. The spleen was the only organ in which activity increased between 2 and 20 h. The presence of hMSC was documented in the spleen, liver, lung, and brain following histology. IV-injected hMSC are transiently trapped in the lungs, can be sequestered in the spleen, and are predominantly eliminated by kidneys. After 20 h, more hMSC are found in the ischemic lesion than into the undamaged cerebral tissue. IV delivery of hMSC could be the initial route for a clinical trial of tolerance. |
| المشرفين على المادة: | 0 (Radiopharmaceuticals) 3B744AG22N (Technetium Tc 99m Exametazime) |
| تواريخ الأحداث: | Date Created: 20091024 Date Completed: 20100520 Latest Revision: 20181201 |
| رمز التحديث: | 20231215 |
| DOI: | 10.3727/096368909X474230 |
| PMID: | 19849895 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1555-3892 |
|---|---|
| DOI: | 10.3727/096368909X474230 |